Allogeneic bone marrow transplantation in the myelodysplastic syndromes

The Myelodysplastic Syndromes: Pathobiology and Clinical Management

Volumn , Issue , 2002, Pages 435-464

  Anderson, Jeanne E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84907272074     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (57)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51:189-199.
2. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:383-389.
3. Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992; 6:52-59.
4. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079-2088.
5. Sanz GF, Sanz MA, Vallespi T, Canizo MC, Torrabadella M, Garcia S, Irriguible D, San Miguel JF. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a mutivariate analysis of prognostic factors in 370 patients. Blood 1989; 74:395-408.
6. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E, Bauters F, Fenaux P. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993; 7:1315-1323.
7. Cazzola M, Anderson JE, Ganser A, Hellstrom-Lindberg E. A patient-oriented approach to treatment of myelodysplastic syndromes. Haematologica 1998; 83:910-935.
8. Silverman LR, Demakos EP, Peterson B, Odchimar-Reissig R, Nelson D, Kornblith AB, Stone R, Holland JC, Powell BL, DeCastro C, Ellerton J, Larson RA, Schiffer CA, Holland JF. A randomized controlled trial of subcutaneous azacitidine (AZA-C) in patients with the myelodysplastic syndrome (MDS): A study of the Cancer and Leukemia Group B (CALGB). Proceedings of ASCO Meeting. J Clin Oncol 1998; 17(suppl):14a.
9. Gassmann W, Schmitz N, Loffler H, De Witte T. Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Semin Hematol 1996; 33: 196-205.
10. Appelbaum FR, Storb R, Ramberg RE, Shulman HM, Buchner CD, Clift RA, Deeg HJ, Fefer A, Sanders J, Stewart P. Allogeneic marrow transplantation in the treatment of preleukemia. Ann Intern Med 1984; 100:689-693.
11. Runde V, de Witte T, Arnold R, Gratwohl A, Hermans J, van Biezen A, Nieder-wieser D, Labopin M, Walter-Noel MP, Bacigalupo A, Jacobsen N, Ljungman P, Carreras E, Kolb HJ, Aul C, Apperley J. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Part of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21:255-261.
12. Arnold R, de Witte T, van Biezen A, Hermans J, Jacobsen N, Runde V, Gratwohl A, Apperley JF. Unrelated bone marrow transplantation in patients with myelodys-plastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transplant 1998; 21: 1213-1216.
13. Anderson JE, Appelbaum FR, Fisher LD, Schoch G, Shulman H, Anasetti C, Ben-singer WI, Bryant E, Buckner CD, Doney K, Martin PJ, Sanders JE, Sullivan KM, Thomas ED, Witherspoon RP, Hansen JA, Storb R. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993; 82:677-681.
14. Sutton L, Chastang C, Ribaud P, Jouet JP, Kuentz M, Attal M, Reiffers J, Tigaud JM, Rio B, Dauriac C, Legros M, Dreyfus F, Lioure B, Troussard X, Milpied N, Witz F, Oriol P, Cahn JY, Michallet M, Gluckman E, Ifrah N, Pico JL, Vilmer E, Leblond V. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients. Societe Francaise de Greffe de Moelle. Blood 1996; 88:358-365.
15. Nevill TJ, Fung HC, Shepherd JD, Horsman DE, Nantel SH, Klingemann HG, Forrest DL, Toze CL, Sutherland HJ, Hogge DE, Naiman SC, Le A, Brockington DA, Barnett MJ. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 1998; 92:1910-1917.
16. Ballen KK, Gilliland DG, Guinan EC, Hsieh CC, Parsons SK, Rimm IJ, Ferrara JL, Bierer BE, Weinstein HJ, Antin JH. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant 1997; 20:737-743.
17. Locatelli F, Niemeyer C, Angelucci E, Bender-Gotze C, Burdach S, Ebell W, Friedrich W, Hasle H, Hermann J, Jacobsen N, Klingebiel T, Kremens B, Mann G, Pession A, Peters C, Schmid HJ, Stary J, Suttorp M, Uderzo C, van’t Veer-Korthof ET, Vossen J, Zecca M, Zimmermann M. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood. J Clin Oncol 1997; 15:566-573.
18. O’Donnell MR, Long GD, Parker PM, Niland J, Nademanee A, Amylon M, Chao N, Negrin RS, Schmidt GM, Slovak ML, Smith EP, Snyder DS, Stein AS, Traweek T, Glume KG, Forman SJ. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol 1995; 13: 2973-2979.
19. Mattijssen V, Schattenberg A, Schaap N, Preijers F, De Witte T. Outcome of allogeneic bone marrow transplantation with lymphocyte-depleted marrow grafts in adult patients with myelodysplastic syndromes. Bone Marrow Transplant 1997; 19:791-794.
20. Anderson JE, Appelbaum FR, Schoch G, Gooley T, Anasetti C, Bensinger WI, Bryant E, Buckner CD, Chauncey T, Clift RA, Deeg JH, Doney K, Flowers M, Hansen JA, Martin PJ, Matthews DC, Nash RA, Sanders JE, Shulman H, Sullivan KM, Witherspoon RP, Storb R. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 1996; 14:220-226.
21. Anderson JE, Appelbaum FR, Schoch G, Gooley T, Anasetti C, Bensinger WI, Bryant E, Buckner CD, Chauncey TR, Clift RA, Doney K, Flowers M, Hansen JA, Martin PJ, Matthews DC, Sanders JE, Shulman H, Sullivan KM, Witherspoon RP, Storb R. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood 1996; 87:5158.
22. Ratanatharathorn V, Karanes C, Uberti J, Lum LG, de Planque MM, Schultz KR, Cronin S, Dan ME, Mohamed A, Hussein M, Sensenbrenner LL. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplas-tic syndromes. Blood 1993; 81:2194-2199.
23. Demuynck H, Verhoef GE, Zachee P, Emonds MP, van der Schueren E, van den Berghe H, Vandenberghe P, Casteels-Van Daele M, Boogaerts MA. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors. Bone Marrow Transplant 1996; 17:745-751.
24. Appelbaum FR, Barrall J, Storb R, Ramberg R, Doney K, Sale GE, Thomas ED. Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia. Exp Hematol 1987; 15:1134-1139.
25. Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 1998; 12(suppl 1):S25-S29.
26. Deeg HJ, Shulman HM, Anderson JE, Bryant EM, Gooley TA, Slattery JT, Anasetti C, Fefer A, Storb R, Appelbaum FR. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 2000; 95:1188-1194.
27. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995; 86:3542-3552.
28. Stone RM. Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress. Blood 1994; 83:3437-3440.
29. Witherspoon RP, Deeg HJ. Allogeneic bone marrow transplantation for secondary leukemia or myelodysplasia. Haematologica 1999; 84:1085-1087.
30. Le Maignan C, Ribaud P, Maraninchi D, et al. Bone marrow transplantation for mutagen-related leukemia or myelodysplasia. Exper Hematol 1990; 18:660.
31. Bandini G, Rosti G, Calori E, Albertazzi L, Tura S. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome. Br J Haematol 1990; 75:442-444.
32. De Witte T. Response to “Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome.” Br J Haematol 1990; 75:443-444.
33. Bunin NJ, Casper JT, Chitambar C, Hunter J, Truitt R, Menitove J, Camitta BM, Ash R. Partially matched bone marrow transplantation in patients with myelodysplastic syndromes. J Clin Oncol 1988; 6:1851-1855.
34. Yakoub-Agha I, de La Salmoniere P, Ribaud P, Sutton L, Wattel E, Kuentz M, Jouet JP, Marit G, Milpied N, Deconinck E, Gratecos N, Leporrier M, Chabbert I, Caillot D, Damaj G, Dauriac C, Dreyfus F, Francois S, Molina L, Tanguy ML, Chevret S, Gluckman E. Allogeneic bone marrow transplantation for therapy-related myelodys-plastic syndrome and acute myeloid leukemia: a long-term study of 70 patients— report of the French society of bone marrow transplantation. J Clin Oncol 2000; 18: 963-971.
35. Castro-Malaspina H, Collins JER, Gajewski J, Harris R, Ramsay N, Deeg HJ Unrelated donor marrow transplantation for myelodysplastic syndromes (MDS). Blood 1997; 90:106a.
36. Anderson JE, Anasetti C, Appelbaum FR, Schoch G, Gooley TA, Hansen JA, Buckner CD, Sanders JE, Sullivan KM, Storb R. Unrelated donor marrow transplanation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol 1996; 93:59-67.
37. Sierra J, Carreras E, Rozman C, Champlin R, Rowlings P, Horowitz M. Bone marrow transplantation for myelodysplasia: the IBMTR data. Leuk Res 1997; 21(suppl): S51.
38. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A, Gajewski J, Hansen JA, Henslee-Downey J, McCullough J, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328:593-602.
39. Dresse MF, Boogaerts M, Vermylen C, Noens L, Ferrant A, Schots R, Doyen C, Bron D, Berneman Z, Ferster A, Benoit Y, Demuynck H, Beguin Y. The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor. Haematologica 1999; 84:637-642.
40. Bjerke J, Anasetti C, Gooley T, Appelbaum F, Hansen J, Anderson J, Slattery J, Storb R, Deeg HJ. Unrelated donor (URD) bone marrow transplantation (BMT) for refractory anemia (RA). Blood 1998; 92(suppl):142a.
41. Coplean EA, Penza SL, Elder PJ, Ezzone SA, Scholl MD, Bechtel TP, Belt PS, Avalos BR. Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation. Bone Marrow Transplant 2000; 25:1219-1222.
42. Anderson JE, Gooley TA, Schoch G, Anasetti C, Bensinger WI, Clift RA, Hansen JA, Sanders JE, Storb R, Appelbaum FR. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 1997; 89:2578-2585.
43. Alessandrino EP, Astori C, Van Lint MT, et al. Myelodysplastic syndrome or leukemia developing after MDS treated by allogeneic bone marrow transplantation: outcome of 90 adult patients. Leuk Res 1997; 21(suppl):S52.
44. DeWitte T, Zwaan F, Hermans J, Vernant J, Kolb H, Vossen J, Lonnqvist B, Beelen D, Ferrant A, Gmur J, et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 1990; 74:151-155.
45. Niemeyer C, Duffner U, Bender-Gotze C, Dini G, Ebell W, Egeler M, Hasle H, Heilmann C, Klingebiehl T, Kremens B, Messina C, Nurnberger W, Uderzo C, Zintl F, Zecca M, Nollke P, Locatelli F. AML-type intensive chemotherapy prior to stem cell transplantation (SCT) does not improve survival in children and adolescents with primary myelodysplastic syndromes (MDS). Blood 2000; 96(suppl):521a.
46. Clift RA, Buckner CD, Appelbaum FR, Schoch G, Petersen FB, Bensinger WI, Sanders J, Sullivan KM, Storb R, Singer J, Hansen JA, Thomas D. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 1992; 10:1723-1729.
47. Karanes C, Abella E, Du W, Klein J, Dansey R, Cassells L, Peters W, Baynes R. Allogeneic bone marrow transplantation (alloBMT) in myelodysplastic syndromes (MDS). Blood 1998; 92:659a.
48. Anderson JE, Appelbaum FR, Deeg HJ, Storb R. Phase II study of busulfan (BU) and total body irradiation (TBI) as a novel preparative regimen in allogeneic marrow transplantation (BMT) for advanced myelodysplastic syndrome. Leuk Res 1999; 23(suppl):S83.
49. 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1997; 90(suppl): 417a.
50. Castro-Malaspina H, Childs B, Papadopoulos E, et al. T-cell depleted (SBA-E-) bone marrow transplantation for myelodysplastic syndromes. Leuk Res 1997; 2l(suppl): S51.
51. O’Donnell PV, Noga SJ, Grever M, Vogelsang GB, Jones RJ. Using engineered allografts to improve transplant outcome in myelodysplastic syndrome (MDS). Blood 1997; 90(suppl):229a.
52. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, O’Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Prezepiorka D, Koller C, Kornblau S, Korbling M, Keating M, Kantarjian H, Champlin R. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89:4531-4536.
53. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
54. Parker JE, Shafi T, Mijovic A, Pagliuca A, Devereux S, Garg M, Yin JA, Potter M, Prentice HG, Byrne J, Russell NH, Mufti GJ. Allogeneic stem cell transplantation (SCT) in MDS:interim results of outcome following non-myeloablative conditioning compared to standards preparative regimens Blood 2000; 96(suppl):554a.
55. Cao TM, McSweeney PA, Niederwieser D, Sahebi F, Sandmaier BM, Chauncey TR, Maris MB, Forman SJ, Blume KG, Shizuru JA, Storb RF. Non-myeloablative allogeneic hematopoietic cell transplantation (AHCT) for patients with myelodys-plastic syndromes (MDS) and myeloproliferative disorders (MPD). Blood 2000; 96(suppl):170a.
56. Rezvani K, Lalancette M, Szydlo R, Mackinnon S, Blaise D, Slavin S, Alessandrino EP, Michallet M, Niederwieser N, Apperley J, Frassoni F. Non-myeloablative stem cell transplant (NMSCT) in AML, ALL, and MDS: Disappointing outcome for patients with advanced phase disease. Blood 2000; 96(suppl):479a.
57. Shimoni A, Khouri I, Donato M, Anderlini P, Andersson B, Ueno N, Champlin R, Giralt S. Allogeneic transplantation with non-myeloablative or reduced intensity conditioning: the intensity of the conditioning regimen is related to outcome in patients with active disease but not in those in remission at the time of transplantation. Blood 2000; 96(suppl):199a.